Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

25 mars 2026 12h47 HE | Source: Onconetix, Inc.

Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration

Realbotix Humanoid Robot — Ericsson’s First Enterprise Robotics Client — Featured as Live Connected Endpoint in Pre-Standard 6G Over-the-Air Trial at Ericsson’s U.S. Headquarters; Onconetix Has...
23 mars 2026 08h30 HE | Source: Onconetix, Inc.

Onconetix, Inc. Announces 1-for-5 Reverse Stock Split

CINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development,...
12 févr. 2026 08h00 HE | Source: Onconetix, Inc.

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company

A leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- ...
26 sept. 2025 08h30 HE | Source: Onconetix, Inc.

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and...
26 sept. 2025 08h15 HE | Source: Onconetix, Inc.

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and...
22 sept. 2025 08h00 HE | Source: Onconetix, Inc.

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and...
16 juil. 2025 08h17 HE | Source: Onconetix, Inc.

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company...
16 juin 2025 08h22 HE | Source: Onconetix, Inc.

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

CINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and...
11 juin 2025 11h30 HE | Source: Onconetix, Inc.

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and...
22 mai 2025 16h50 HE | Source: Onconetix, Inc.

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May...

Page suivante